Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Cited by
DNA Origami as an In Vivo Drug Delivery Vehicle for Cancer Therapy
Zhang, Q., Jiang, Q., Li, N., Dai, L., Liu, Q., Song, L., Wang, J., Li, Y., Tian, J., Ding, B., et al. (2014) · ACS Nano · doi:10.1021/nn502058j · Cited by 643
Effects of systemic chemotherapy on the liver
Ramadori, G., & Cameron, S. (2010) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31651-5 · Cited by 132
New Paradigms in Post-hepatectomy Liver Failure
Golse, N., Bucur, P. O., Adam, R., Castaing, D., Sa Cunha, A., & Vibert, E. (2013) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-012-2048-6 · Cited by 100
“, 51 Bevacizumab does not appear to alter the volume gain after PVE(52) and perhaps prevents vascular lesions induced by oxaliplatin.(53) In murine experimental models, sorafenib does not impair liver regeneration if stopped before surgery.”
Metadata
- Authors
- Klinger, M., Eipeldauer, S., Hacker, S., Herberger, B., Tamandl, D., Dorfmeister, M., Koelblinger, C., Gruenberger, B., & Gruenberger, T.
- Venue
- European Journal of Surgical Oncology (EJSO)
- Publisher
- Elsevier BV
- Published
- 2009-05
- Volume
- 35
- Issue
- 5
- Pages
- 515-520
- ISSN
- 0748-7983 (ISSN-L)
- OpenAlex
- W2015155974
- Cited by
- 158
- References
- 3
- FWCI
- 10.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. https://app.cochat.ai/papers/10.1016/j.ejso.2008.12.013
- The paper
- Klinger, M., Eipeldauer, S., Hacker, S., Herberger, B., Tamandl, D., Dorfmeister, M., Koelblinger, C., Gruenberger, B., & Gruenberger, T. (2009). Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. European Journal of Surgical Oncology (EJSO). https://doi.org/10.1016/j.ejso.2008.12.013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.